Loading insider details...
Latest Form 4 (Oct 2, 2026): Exercise/Conversion of 4,224 QTRX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Quanterix Corp (QTRX) | Exercise/Conversion | 4,224 | n/a |
| Jun 22, 2026 | Acrivon Therapeutics, Inc. (ACRV) | Grant/Award | 20,275 | n/a |
| May 20, 2026 | Acrivon Therapeutics, Inc. (ACRV) | Grant/Award | 9,366 | n/a |
| Jan 15, 2026 | Quanterix Corp (QTRX) | Grant/Award | 23,372 | n/a |
| Jun 17, 2025 | Acrivon Therapeutics, Inc. (ACRV) | Grant/Award | 20,275 | n/a |
| Jan 6, 2025 | Quanterix Corp (QTRX) | Grant/Award | 7,435 | n/a |
| Oct 3, 2024 | Quanterix Corp (QTRX) | Grant/Award | 12,800 | n/a |
| May 7, 2024 | Vigil Neuroscience, Inc. (VIGL) | Disposition to Issuer | 282,000 | n/a |
| Mar 1, 2024 | Vigil Neuroscience, Inc. (VIGL) | Grant/Award | 463,000 | n/a |
| Feb 9, 2024 | Acrivon Therapeutics, Inc. (ACRV) | Grant/Award | 32,500 | n/a |